Leucettinib-92 (compound 92) is an inhibitor of DYRK/CLK kinase, The IC50s are 147 nM (CLK1), 39 nM (CLK2), 5.2 nM (CLK4), 0.8 μM (CLK3), 124 nM (DYRK1A), 204 nM (DYRK1B), 0.16 μM (DYRK2), respectively. 1.0 μM (DYRK3), 0.52 μM (DYRK4), 2.78 μM (GSK3)[1].

Leucic acid is an amino acid metabolite[1].

Leucine dehydrogenase, Microorganism (EC 1.4.1.9) can be purified from Bacillus spheroides. Leucine dehydrogenase catalyzed the oxidative deamination of L-leucine, L-valine, L-isoleucine, L-norvaline, L-alpha-aminobutyrate, and L-norleucine, and the reductive amination of their keto analogues[1].

Leucine dehydrogenase, Microorganism (EC 1.4.1.9) can be purified from Bacillus spheroides. Leucine dehydrogenase catalyzed the oxidative deamination of L-leucine, L-valine, L-isoleucine, L-norvaline, L-alpha-aminobutyrate, and L-norleucine, and the reductive amination of their keto analogues[1].

Leucocrystal violet-d6 is the deuterium labeled Leucocrystal violet[1]. Leucocrystal violet is a triphenylmethane dye which can be used to detect antimony in environmental and biological samples using spectrophotometric techniques[2][3].

Leucodin is a sesquiterpene lactone derived from Gynoxys verrucosa. Leucodin has cytotoxic activity on human leukemia cells[1].

Leucokinin I is a peptide that stimulates contraction of the anterior midgut and hindgut muscles involved in feeding in Rhodnius prolixus but not absorption in the anterior midgut[1].

Leucomycin A1 is a main component of the leucomycin complex produced by Streptomyces kitasatoensis, Leucomycin A1 is an antibiotic[1].

Leucomycin tartrate (Kitasamycin tartrate) is a potent 16-membered macrolideantibiotic[1].

Leucopelargonidin (compound IV) can be isolated from Connarus monocarpus[1].

Leucovorin-d4 (Leucovorin-d4) calcium hydrate, >90% is a deuterated labeled Folinic acid (Leucovorin, HY-17556). Folinic acid (Leucovorin) is a biological folic acid and is generally administered along with Methotrexate (MTX) (HY-14519) as a rescue agent to decrease MTX-induced toxicity[1].

Leucyl aminopeptidase is a metallopeptidase that cleave N-terminal residues from proteins and peptides. Leucyl aminopeptidase serves as transcriptional repressors to control pyrimidine, alginate and cholera toxin biosynthesis, as well as mediate site-specific recombination events in plasmids and phages[1].

Leucylproline, a dipeptide, plays important roles in the medium-dependent regulation of proteinase activity[1].

Leukotriene C4 methyl ester is a methyl ester of leukotriene C4. Leukotriene C4 methyl ester can be used for the research of psoriasis[1].

Leumorphin, human is a potent kappa opioid receptor (κ opioid receptor) agonist. Leumorphin, human inhibits the contraction of the myenteric plexus-longitudinal muscle preparation of the guinea pig ileum[1].

Leuprolide Acetate EP Impurity D is the impurity of Leuprolide (Leuprorelin)[1].

Levanase is a slime-dissolving enzyme of Rhodotorula species. Levanase performs random hydrolysis of β-2,6 fructofuranosyl linkages in β-2,6 fructans containing more than 3 fructose units[1].

Levanase is a slime-dissolving enzyme of Rhodotorula species. Levanase performs random hydrolysis of β-2,6 fructofuranosyl linkages in β-2,6 fructans containing more than 3 fructose units[1].

Levemopamil hydrochloride is a blood-brain barrier penetrable calcium channel blocker and a 5-HT2 antagonist. Levemopamil hydrochloride can be used for temporary occlusion and neurological disease research[1].

Levilimab (BCD-089) is a fully human anti-interleukin-6 receptor (IL-6R) monoclonal antibody. Levilimab is an inflammation-alleviating antibody. Levilimab can be used for the research of rheumatoid[1].

Levine Eosin-Methylene Blue Agar Medium (Levine EMB Agar) is a weakly selective medium for the isolation of intestinal pathogens, especially E. coli. The composition of 1 liter of Levine Eosin-Methylene Blue Agar Medium: 10.0 g Peptone, 10.0 g lactose, 2.0 g dipotassium hydrogen phosphate, 15.0 g agar, 0.4 g eosin, 0.065 g methylene blue[1].

Levocetirizine-d4 ((R)-Cetirizine-d4) is the deuterium-labeled Levocetirizine (HY-B0814)[1]. Levocetirizine ((R)-Cetirizine) is a third-generation peripheral H1-receptor antagonist. Levocetirizine is an antihistaminic agent which is the R-enantiomer of Cetirizine. Levocetirizine has a higher affinity for the histamine H1-receptor than (S)-Cetirizine and can effectively treat allergic rhinitis and chronic idiopathic urticaria[2].

Levofuraltadone (NF-602) is an antibacterial and antiparasitic agent. Levofuraltadone has anti-trypanosomiasis activity and can be used in the study of human african trypanosomiasis as well as bacterial infections[1].

Levoglucosan-13C6 is the 13C labeled Levoglucosan[1]. Levoglucosan (1,6-Anhydro-β-D-glucopyranose) is an anhydrosugar produced through glucan pyrolysis and is widely found in nature[2].

Levoglucosenone is a biochemical reagent that can be used as a biological material or organic compound for life science related research.

Levoglucosenone is a biochemical reagent that can be used as a biological material or organic compound for life science related research.

Levomedetomidine-d8 is the deuterium labeled Levomedetomidine[1].

Levomefolic acid-13C,d3is the deuterium labeledLevomefolic acid(HY-14781)[1]. Levomefolic acid (5-MTHF) is an orally active, brain-penetrant natural active form of folic acid and is one of the most widely used folic acid food supplements[2][3].

Levomefolic acid-13C5 is the 13C labeled Levomefolic acid[1]. Levomefolic acid (5-MTHF) is an orally active, brain-penetrant natural active form of folic acid and is one of the most widely used folic acid food supplements[2][3].

Levonantradol (l-Nantradol) hydrochloride is an analog of delta (9)-tetrahydrocannabinol. Levonantradol acting as a potent anti-analgesic agent[1].

Levonorgestrel (Standard) is the analytical standard of Levonorgestrel. This product is intended for research and analytical applications.

Levormeloxifene (fumarate) is a stable salt form of Levormeloxifene. Levormeloxifene (fumarate) is an estrogen receptor modulator that plays an important role in prevention of postmenopausal bone loss[1].

Levothyroxine-d3 is the deuterium labeled Levothyroxine[1].

Levoxadrol is an active enantiomer of dexoxadrol[1].

Levulinic acid-d5 is the deuterium labeled Levulinic acid[1]. Levulinic acid is a precursor for the synthesis of biofuels, such as ethyl levulinate[2].

Levulinic acid-d5 is the deuterium labeled Levulinic acid[1]. Levulinic acid is a precursor for the synthesis of biofuels, such as ethyl levulinate[2].

Lexanersen sodium is an antisense oligonucleotide used for the study of Huntington’s disease[1].

Leyk is a a biochemical assay reagent[1].

Leyk is a a biochemical assay reagent[1].

Leyk is a a biochemical assay reagent[1].

LfcinB 17–28 TFA has weak antimicrobial activity (MIC: 200 μM against E. coli). LfcinB 17–28 TFA is a fragment of Bovine Lactoferricin (LfcinB)[1].

LFHP-1c is an PGAM5 inhibitor with neuroprotective activity in brain ischemic stroke. LFHP-1c protects blood-brain barrier integrity from ischemia-induced injury. LFHP-1c binds to endothelial PGAM5 to inhibit the activity of PGAM5 phosphatase and the interaction of PGAM5 with NRF2. LFHP-1c exhibits in vitro and in vivo protection[1].

LFHP-1c is an PGAM5 inhibitor with neuroprotective activity in brain ischemic stroke. LFHP-1c protects blood-brain barrier integrity from ischemia-induced injury. LFHP-1c binds to endothelial PGAM5 to inhibit the activity of PGAM5 phosphatase and the interaction of PGAM5 with NRF2. LFHP-1c exhibits in vitro and in vivo protection[1].

LFHP-1c is an PGAM5 inhibitor with neuroprotective activity in brain ischemic stroke. LFHP-1c protects blood-brain barrier integrity from ischemia-induced injury. LFHP-1c binds to endothelial PGAM5 to inhibit the activity of PGAM5 phosphatase and the interaction of PGAM5 with NRF2. LFHP-1c exhibits in vitro and in vivo protection[1].

LFHP-1c is an PGAM5 inhibitor with neuroprotective activity in brain ischemic stroke. LFHP-1c protects blood-brain barrier integrity from ischemia-induced injury. LFHP-1c binds to endothelial PGAM5 to inhibit the activity of PGAM5 phosphatase and the interaction of PGAM5 with NRF2. LFHP-1c exhibits in vitro and in vivo protection[1].

LFHP-1c is an PGAM5 inhibitor with neuroprotective activity in brain ischemic stroke. LFHP-1c protects blood-brain barrier integrity from ischemia-induced injury. LFHP-1c binds to endothelial PGAM5 to inhibit the activity of PGAM5 phosphatase and the interaction of PGAM5 with NRF2. LFHP-1c exhibits in vitro and in vivo protection[1].

LFM-A13 is a potent BTK, JAK2, PLK inhibitor, inhibits recombinant BTK, Plx1 and PLK3 with IC50s of 2.5 μM, 10 μM and 61 μM. LFM-A13 has antiproliferative activity and anticancer activity. LFM-A13 can be used in cancer-related research[1][3][4]

LFS-1107 is a reversible CRM1 inhibitor (Kd: 12.5 pM). LFS-1107 can selectively eliminate extranodal natural killer/T cell lymphoma (ENKTL) cells and can be used for cancer research[1].

LG 82-4-01 is a thromboxane (TX) synthetase specific inhibitor, with an IC50 of 1.3 μM[1].

LG101506 is a selective and orally active RXR modulator with a Ki of 2.7 nM for RXRα. LG101506 can be used for the research of type 2 diabetes and cancer[1][2].